5AM Ventures Leads $45M Series B Financing for Camp4 Therapeutics

Choate represented 5AM Ventures in a $45M Series B financing round for Camp4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gene expression. CAMP4 is combining its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that enable tunable upregulation of gene expression to treat disease. This investment will propel the next phase of Camp4’s scientific strategy, significantly expand its platform, and advance multiple preclinical RNA therapies into human testing.

5AM Ventures and Northpond Ventures joined existing investors Andreessen Horowitz, Polaris Partners and The Kraft Group in this financing.